Vice President
Venatorx
Mary Beth Dorr, PhD. is the Vice President of Clinical Science at Venatorx Pharmaceuticals, where she is responsible for planning and executing clinical development across Venatorx’s anti-infectives portfolio, specifically cefepime-taniborbactam and ceftibuten-ledaborbactam. Dr. Dorr has greater than 35 years of Pharmaceutical Industry experience, including over 25 years in anti-infective drug development.